Peginterferon to reduce relapse after stopping hepatitis B treatment
Part of Digestive system, Infections clinical trials.
This trial tests whether adding pegylated interferon alfa-2b can help people with hepatitis B stay virus-free after they stop their current oral antiviral medication. It is for patients who have had undetectable virus for over 3 years and have low levels of hepatitis B surface antigen.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a type of hepatitis B called HBeAg-negative and have been taking oral antivirals for at least 3 years with no detectable virus.
- Before starting antivirals, you had HBsAg-positive, HBeAg-negative, and HBsAb-negative blood tests.
- Your liver stiffness measurement is 7.4 kPa or less (no significant scarring).
- Your HBsAg level is 1000 IU/mL or lower.
- You are willing to stop your current hepatitis B medication and sign consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a long-acting interferon medication can help people with chronic hepatitis B who have already received interferon treatment clear the hepatitis B virus more completely. It's designed for patients whose virus levels dropped significantly during their first treatment but haven't gone away.
This study tests a lower dose of pegylated interferon for people with chronic hepatitis B whose virus levels dropped significantly during a previous interferon treatment. It aims to see if a second round can further reduce or clear the virus.
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
This study tests whether additional peginterferon treatment can further reduce the virus in the liver for people with chronic hepatitis B who have already reached a clinical cure. You would need to have two liver biopsies to check the virus levels.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.